Selective, high affinity 5-HT1A
receptor antagonist (Ki
= 0.6 nM in vitro
). Enhances the action of selective 5-HT reuptake inhibitors and reverses citalopram
-induced (Cat. No. 1427) inhibition of serotonergic cell firing.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from AstraZeneca
Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1A receptor antagonists.
Larsson et al.
The 5-HT1A receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing.
Arborelius et al.
The pharmacological characterization of a novel selective 5-hydroxytryptamine-1A receptor antagonist, NAD-299.
Johansson et al.